Electronic Resource
Comparative effectiveness in multiple sclerosis: A methodological comparison
| العنوان: | Comparative effectiveness in multiple sclerosis: A methodological comparison |
|---|---|
| المؤلفون: | Roos, I, Diouf, I, Sharmin, S, Horakova, D, Havrdova, EK, Patti, F, Shaygannejad, V, Ozakbas, S, Izquierdo, G, Eichau, S, Onofrj, M, Lugaresi, A, Alroughani, R, Prat, A, Girard, M, Duquette, P, Terzi, M, Boz, C, Grand'Maison, F, Sola, P, Ferraro, D, Grammond, P, Turkoglu, R, Buzzard, K, Skibina, O, Yamou, B, Altintas, A, Gerlach, O, van Pesch, V, Blanco, Y, Maimone, D, Lechner-Scott, J, Bergamaschi, R, Karabudak, R, McGuigan, C, Cartechini, E, Barnett, M, Hughes, S, Sa, MJ, Solaro, C, Ramo-Tello, C, Hodgkinson, S, Spitaleri, D, Soysal, A, Petersen, T, Granella, F, de Gans, K, McCombe, P, Ampapa, R, Van Wijmeersch, B, van der Walt, A, Butzkueven, H, Prevost, J, Sanchez-Menoyo, JL, Laureys, G, Gouider, R, Castillo-Trivino, T, Gray, O, Aguera-Morales, E, Al-Asmi, A, Shaw, C, Deri, N, Al-Harbi, T, Fragoso, Y, Csepany, T, Sempere, AP, Trevino-Frenk, I, Schepel, J, Moore, F, Malpas, C, Kalincik, T |
| بيانات النشر: | SAGE PUBLICATIONS LTD 2023-03 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models. OBJECTIVE: To use the comparative effectiveness of fingolimod vs natalizumab to compare the results obtained with propensity score matching and marginal structural models. METHODS: Patients with clinically isolated syndrome or relapsing remitting MS who were treated with either fingolimod or natalizumab were identified in the MSBase registry. Patients were propensity score matched, and inverse probability of treatment weighted at six monthly intervals, using the following variables: age, sex, disability, MS duration, MS course, prior relapses, and prior therapies. Studied outcomes were cumulative hazard of relapse, disability accumulation, and disability improvement. RESULTS: 4608 patients (1659 natalizumab, 2949 fingolimod) fulfilled inclusion criteria, and were propensity score matched or repeatedly reweighed with marginal structural models. Natalizumab treatment was associated with a lower probability of relapse (PS matching: HR 0.67 [95% CI 0.62-0.80]; marginal structural model: 0.71 [0.62-0.80]), and higher probability of disability improvement (PS matching: 1.21 [1.02 -1.43]; marginal structural model 1.43 1.19 -1.72]). There was no evidence of a difference in the magnitude of effect between the two methods. CONCLUSIONS: The relative effectiveness of two therapies can be efficiently compared by either marginal structural models or propensity score matching when applied in clearly defined clinical contexts and in sufficiently powered cohorts. |
| مصطلحات الفهرس: | Journal Article |
| URL: | NHMRC/1129189 NHMRC/1140766 NHMRC/1157717 |
| الاتاحة: | Open access content. Open access content |
| Other Numbers: | UMV oai:jupiter.its.unimelb.edu.au:11343/333578 Roos, I., Diouf, I., Sharmin, S., Horakova, D., Havrdova, E. K., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Prat, A., Girard, M., Duquette, P., Terzi, M., Boz, C., Grand'Maison, F. ,... Kalincik, T. (2023). Comparative effectiveness in multiple sclerosis: A methodological comparison. MULTIPLE SCLEROSIS JOURNAL, 29 (3), pp.326-332. https://doi.org/10.1177/13524585231151394. 10.1177/13524585231151394 1477-0970 1352-4585 1397538800 |
| المصدر المساهم: | UNIV OF MELBOURNE From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1397538800 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |